+ count, 90 cells/mm 3 ) who were hospitalized with pneumonia and who had sputum and/or other specimens that tested concurrently positive for both Mycobacterium tuberculosis and Pneumocystis carinii. The most common chest x-ray abnormality was a reticulonodular pattern or bilateral infiltrates ( ). n p 26 Serum lactate dehydrogenase levels were elevated in 17 (85%) of 20 of patients tested (mean value, 2208 U/ L). Mean O 2 saturation and PO 2 were 89% and 64 mm Hg, respectively. A majority (24 patients [62%]) received both antituberculous and anti-PCP therapy (17 with steroids), and 22 improved. All ten patients who received no treatment for PCP improved and were discharged from the hospital, whereas 4 (
Pneumocystis carinii pneumonia (PCP) and tuberculosis (TB) caused by Mycobacterium tuberculosis are common pulmonary pathogens in patients infected with HIV; their relative frequencies depend on geographic location. P. carinii is the most frequent cause of opportunistic pneumonia in patients with HIV and AIDS in the United States and Europe [1] , whereas, in Africa, M. tuberculosis is the predominant agent [2, 3] . Concurrent opportunistic infections in these severely immunosuppressed hosts that involve 1 or more organ systems are well described, but dual pulmonary infection with both P. carinii and M. tuberculosis has been only rarely re-ported [4] [5] [6] [7] ; these articles report bronchoscopic studies of pneumonia in HIV-infected patients or pneumonia noted during antipneumocystis drug trials, and do not involve a case series. During a 22-month period, we retrospectively identified 39 HIV-seropositive patients who were hospitalized with pneumonia, all of whom had dual infection with these organisms, as diagnosed by use of induced sputum analysis. We aimed to determine the frequency of infection; the salient clinical, laboratory, and radiographic features; and the clinical outcomes of patients with HIV/AIDS who have this pulmonary coinfection.
PATIENTS AND METHODS
This retrospective study was conducted at 3 academic hospitals affiliated with the University of the Witwatersrand in Johannesburg, South Africa: Johannesburg General Hospital (a 1700-bed public teaching hospital), Chris Hani Baragwanath Hospital (a 3300-bed public teaching hospital located in the former black township of Soweto), and Sizwe Tropical Diseases Hospital (a 500-bed provincial referral hospital for infectious diseases, mainly TB and HIV). Computerized log books of the Parasitology and Mycobacteriology Reference Laboratories of the South African Institute for Medical Research were retrospectively reviewed in order to identify patients who were hospitalized for pneumonia at the above hospitals from whom P. carinii cysts and M. tuberculosis (by use of acid-fast smear, cultural isolation, or both) were simultaneously detected. For the purpose of the study, concurrent detection was defined as a positive result for tests for both organisms obtained within a period р5 days from the patient's sputum sample, other clinical specimen submission, or both. For patients who had dual infection identified, a medical and radiograph record review was performed to determine demographic and clinical characteristics (age; sex; HIV antibody status; CD4 ϩ lymphocyte count; receipt of P. carinii prophylaxis; previous history of TB; presenting symptoms; pulmonary examination findings; serum lactate dehydrogenase [LDH] ; percentage of oxygen saturation, arterial blood gas PO 2 level, or both; antimicrobial therapy for PCP, TB, or both), radiographic patterns of disease, and clinical course. The obtainment of induced sputum for examination is the preferred procedure for the diagnosis of PCP at the academic hospitals of the University of the Witwatersrand. It is rare that patients will undergo bronchoscopy without a prior sputum induction; because of the labor-intensive nature of bronchoscopy and the limited resources at our institutions, it is provided on a controlled basis. Induced sputum collection consists of the administration of 3% hypertonic saline (via ultrasonic nebulizer) for 5-15 min until productive cough is produced. During the study period, expectorated material submitted for P. carinii direct detection was tested by use of the Merifluor P. carinii test kit (Meridian Diagnostics), a direct immunofluorescence test that uses 2 monoclonal antibodies directed again P. carinii cysts and trophozoites. Induced and noninduced sputum specimens were prepared and the test results were interpreted according to the manufacturer's instructions. Cysts were classified as "scanty," "moderate," or "numerous," as per the semiquantitation reporting system. Examination of sputum samples submitted for acid-fast bacilli detection utilized fluorescent microscopy treated with an auramine O fluorescent acid-fast stain. A patient was considered to have TB if at least 1 sputum specimen showed acidfast bacilli. An aliquot of the sediment was processed by use of the N-acetyl-l-cysteine sodium hydroxide method of decontamination digestion; it was then concentrated and inoculated into a BACTEC 12B culture system. Cultures were analyzed on the BACTEC 460 system (BACTEC, Johnston Laboratories) by means of a radiometric method. The cultures were kept for 4 weeks, and if no growth occurred during this period, the results were considered negative. A back-up culture was also planted on a Lowenstein-Jensen agar slant, incubated for 8 weeks at 35ЊC, and examined weekly. All specimens with positive results had a Ziehl-Neelsen stain performed, as well as a polymerase chain reaction amplification test with 1S 6110-and MPB 64 protein-based DNA probes, to confirm the presence of M. tuberculosis complex [8] .
Statistical analysis of data was performed by use of the x 2 method on the Epi Info computer software program (Centers for Disease Control and Prevention).
RESULTS
For the period of July 1997-May 1999, we retrospectively identified 39 HIV-infected patients from whom M. tuberculosis and P. carinii were simultaneously isolated and we analyzed their clinical courses. Clinical features, radiographic features, and clinical outcome for all study subjects are summarized in 3 ). Only 2 people were receiving PCP prophylaxis, and none had received previous antipneumocystis treatment.
Ten people had a history of previous TB, 3 of whom had been diagnosed within the 2 months before the study hospitalization; 2 of these patients were receiving antituberculous medication at the time of admission, and 1 patient had not complied with the prescribed treatment regimen. Cough (productive in 12 patients and dry in 14 patients; 82%), weight loss (79%), night sweats (45%), dyspnea (34%), and fever (32%) were the most common complaints. Two patients had hemoptysis. Analysis of chest radiographs indicated 1 or more of the following abnormalities: bilateral patchy infiltrates (in 15 patients) or a reticulonodular pattern (in 11), focal consolidation (in 9), hilar or paratracheal lymphadenopathy (in 7), pleural effusion (in 6), necrotization or cavitation (in 5), pericardial effusion (in 2), and bronchopleural fistula (in 1). P. carinii cysts were visualized by use of immunofluorescent smear in all subjects and were semiquantitated as follows: scanty (in 21 patients); moderate (in 17); or numerous (in 1).
Acid-fast bacilli were seen in sputum (in 20 patients), bone marrow (in 1), and lymph node aspirate (in 1). M. tuberculosis was cultured from samples of sputum (in 21 patients); bone marrow (in 10); pleural fluid (in 4); and blood, lymph node, and bronchial washings (in 1 patient each). Serum LDH levels were elevated in 17 (85%) of the 20 subjects tested, with a mean value of 2028 U/L. Three patients had concurrent bacteremia (with Staphylococcus aureus and Mycobacterium avium-intra- A majority of patients (24 patients; 62%) received treatment for both TB and PCP (17 with steroids), and 22 improved. Dual antibiotic therapy was not always begun simultaneously. For several patients who were initially started on regimens directed against either TB or PCP, a positive clinical response was noted only after treatment for the other pathogen was added. Two patients died despite therapy for both TB and PCP (mean durations of antituberculous and antipneumocystis treatment, 3.5 days and 9 days, respectively). Ten patients (6 with moderate P. carinii cysts, 4 with scanty cysts) received no antipneumocystis treatment but improved nonetheless and were discharged from the hospital (
; not significant). Four of 5 patients P ! .3 who didn't receive antituberculous treatment (because of negative results of sputum microscopy, but with subsequent growth of tubercle bacilli in culture) had a poor outcome: 1 died; 1 deteriorated and was discharged to hospice; 1 did not improve and was discharged to hospice; and 1 had partial improvement and was sent home ( ; OR, 43). P ! .0001
DISCUSSION
In severely immunosuppressed hosts with PCP, including patients with HIV/AIDS, coexisting lung infection is not an uncommon occurrence-it is reported in up to 40% of cases in some series [9] [10] [11] . Organisms such cytomegalovirus, Cryptococcus, Aspergillus, herpes simplex, Candida, M. avium intracellulare, and bacteria have been identified in or grown from lung tissue from patients with PCP [9] [10] [11] . Dual pulmonary infection caused by both P. carinii and M. tuberculosis has been only rarely reported [4] [5] [6] [7] . The reports usually derive from bronchoscopic studies of HIV-infected patients with pneumonia or of patients undergoing antipneumocystis drug trials. However, during a 22-month period, we found 39 HIV-infected patients at our institution who had such concurrent infection that was diagnosed by analysis of induced sputum. In fact, 9.9% of all patients with PCP during this period had coexisting TB.
A prospective study (from a hospital servicing a community in the gold mining industry in Gauteng Province of South Africa) comparing autopsy and clinical diagnoses in HIV-infected miners who died from pulmonary processes found dual infection with M. tuberculosis and at least 1 other pathogen present in ∼10% of patients studied postmortem (J. H. Murray, personal communication). In the west, P. carinii is the most frequent cause of opportunistic pneumonia in patients with HIV/AIDS, and in most cases pneumonia represents reactivation of ubiquitously harbored dormant cysts triggered by severe immunosuppression [12] . In South Africa, where the prevalence of TB is a staggering 386 cases per 100,000 people, TB is the most common secondary infection among HIV-infected patients seen at our institutions [2, 3] . The present study demonstrates that in an area with hyperendemic TB, dual pulmonary infection with M. tuberculosis and P. carinii may occur with surprisingly high relative frequency.
The precise contribution of P. carinii infection to active pneumonia in our study's patients is uncertain. It has been shown that serum LDH activity is increased in patients with HIV/ AIDS-related PCP, and the serum LDH test is often used as a surrogate diagnostic and prognostic tool [13] [14] [15] [16] [17] . However, other organisms, including M. tuberculosis [18] , may occasionally be associated with a high (although often more modest) level of serum LDH in HIV-infected patients with pneumonia. In this study, the high percentage of patients with elevated serum LDH levels (85%) and the mean level of 2028 U/L suggests active infection with P. carinii. Certainly, the radiographic patterns of pulmonary infection seen in our study cohort-most commonly with bilateral pulmonary bronchopneumonia or diffuse interstitial infiltration, but also with focal consolidation and necrotization-are compatible with PCP [18] . Other features, such as pleural effusions and hilar and mediastinal lymphadenopathy, were most likely caused by tuberculous infection [18] .
It is unlikely that the P. carinii cysts found in the patients we studied represented asymptomatic and clinically inactive infection. The technique of indirect immunofluorescent monoclonal antibody staining of induced sputum has been found to have an extremely high specificity, and it rarely yields falsepositive results of tests of specimens from patients with HIV/ AIDS [19] . P. carinii cysts persist in the lungs (in bronchoalveolar lavage fluid or biopsy tissue) in a majority of patients, even after apparently successful treatment [20] [21] [22] , and DNA amplification by use of PCR may detect subclinical P. carinii colonization in HIV-infected patients with or without respiratory symptoms in whom cysts cannot be visualized by use of immunofluorescent staining [23] . However, Masur et al. [24] stated that, in the absence of pneumonia, Pneumocystis organisms are rarely, if ever, present in induced sputum from untreated immunosuppressed patients. The concentration of visible cysts identified in the sputum specimens of the patients in our study, 53% of which having been graded as moderate or numerous, suggests active pulmonary infection.
A clear explanation is not apparent for the 10 patients who improved despite not having received antipneumocystis treatment. None of the antituberculous drugs used (isoniazid, rifampin, ethambutol, and pyrazinamide) has any appreciable activity against P. carinii. The CD4 ϩ cell count in HIV-infected patients often decreases during infection with active TB and increases with effective therapy; although we did not monitor CD4 ϩ cells counts during therapy, it is possible that as immune dysfunction improved with TB treatment, host defenses were able to control P. carinii infection. In patients with dual infection, TB appears to exert a more dominant role in these serious diseases which require hospitalization. This is suggested by the clinically significant improvement that allowed hospital discharge for patients who received only antituberculous therapy-a result which stands in contrast to the poor clinical outcome for all 4 individuals who received treatment for PCP but not for TB. From historical controls, it is well known that pneumocystosis in patients with HIV/AIDS may be a subtle disease, with symptoms that last from weeks to months before the patient requires hospitalization. It would seem possible that TB was the acute precipitant of hospitalization in the patients we studied, at a time when their Pneumocystis infections may have been at an earlier stage. However, our study was limited by the incomplete postdischarge follow-up for a majority of patients, and it is possible that people untreated for Pneumocystis may have received anti-PCP therapy after discharge or that their condition may have deteriorated even though they were not readmitted to the same hospital because of pneumonia. In summary, clinicians should be aware that, at some point in the future, persons who have HIV/AIDS may present with concurrent pulmonary TB and PCP, especially in regions that are hyperendemic for TB, and that in these patients, TB seems to account for the most serious symptoms of their disease that require hospitalization. Patients with diffuse pneumonia should be evaluated for P. carinii and M. tuberculosis at the time of initial presentation, and treatment for both of these pathogens is recommended for patients in whom dual pulmonary infection can be documented. The diagnosis of concurrent TB and PCP should be considered for patients who have either one of these infections diagnosed and in whom lack of improvement or clinical deterioration occurs despite seemingly appropriate treatment. In resource-poor areas, where the background prevalence of TB is very high, and where bronchoscopic evaluation it is not available or easily accessible, empiric therapy directed against both of these pathogens may be reasonable for patients who are hospitalized with PCP and who are unresponsive to 7-10 days of appropriate treatment.
